These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 29563526)

  • 1. CISNE: An accurate description of dose-effect and synergism in combination therapies.
    García-Fuente A; Vázquez F; Viéitez JM; García Alonso FJ; Martín JI; Ferrer J
    Sci Rep; 2018 Mar; 8(1):4964. PubMed ID: 29563526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction index and different methods for determining drug interaction in combination therapy.
    Lee JJ; Kong M; Ayers GD; Lotan R
    J Biopharm Stat; 2007; 17(3):461-80. PubMed ID: 17479394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. bayesynergy: flexible Bayesian modelling of synergistic interaction effects in in vitro drug combination experiments.
    Rønneberg L; Cremaschi A; Hanes R; Enserink JM; Zucknick M
    Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34308471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rational approach to the clinical protocol design for drug combinations: a review.
    Chang TT; Chou TC
    Acta Paediatr Taiwan; 2000; 41(6):294-302. PubMed ID: 11198934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances and limitations in the evaluation of analgesic combination therapy.
    Black DR; Sang CN
    Neurology; 2005 Dec; 65(12 Suppl 4):S3-6. PubMed ID: 16385102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigating antimalarial drug interactions of emetine dihydrochloride hydrate using CalcuSyn-based interactivity calculations.
    Matthews H; Deakin J; Rajab M; Idris-Usman M; Nirmalan NJ
    PLoS One; 2017; 12(3):e0173303. PubMed ID: 28257497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A classification model to predict synergism/antagonism of cytotoxic mixtures using protein-drug docking scores.
    Boik JC; Newman RA
    BMC Pharmacol; 2008 Jul; 8():13. PubMed ID: 18664274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies.
    Chou TC
    Pharmacol Rev; 2006 Sep; 58(3):621-81. PubMed ID: 16968952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemogenomic model identifies synergistic drug combinations robust to the pathogen microenvironment.
    Cokol M; Li C; Chandrasekaran S
    PLoS Comput Biol; 2018 Dec; 14(12):e1006677. PubMed ID: 30596642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Covariates in Pharmacometric Repeated Time-to-Event Models: Old and New (Pre)Selection Tools.
    Goulooze SC; Krekels EHJ; Hankemeier T; Knibbe CAJ
    AAPS J; 2018 Dec; 21(1):11. PubMed ID: 30565031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of drug interactions.
    Bijnsdorp IV; Giovannetti E; Peters GJ
    Methods Mol Biol; 2011; 731():421-34. PubMed ID: 21516426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A checkerboard method to evaluate interactions between drugs.
    Martinez-Irujo JJ; Villahermosa ML; Alberdi E; Santiago E
    Biochem Pharmacol; 1996 Mar; 51(5):635-44. PubMed ID: 8615900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and sample size for evaluating combinations of drugs of linear and loglinear dose-response curves.
    Fang HB; Tian GL; Li W; Tan M
    J Biopharm Stat; 2009 Jul; 19(4):625-40. PubMed ID: 20183430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experimental design and interaction analysis of combination studies of drugs with log-linear dose responses.
    Fang HB; Ross DD; Sausville E; Tan M
    Stat Med; 2008 Jul; 27(16):3071-83. PubMed ID: 18186545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design.
    Chou TC; Motzer RJ; Tong Y; Bosl GJ
    J Natl Cancer Inst; 1994 Oct; 86(20):1517-24. PubMed ID: 7932806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Communicating synergism in drug combination studies.
    Brodkin J; Shannon HE
    Arzneimittelforschung; 2000 Aug; 50(8):765-7. PubMed ID: 10994162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new method for identification of outliers in immunogenicity assay cut point data.
    Zhang J; Arends RH; Kubiak RJ; Roskos LK; Liang M; Lee N; Chen CC; Yang H
    J Immunol Methods; 2020; 484-485():112817. PubMed ID: 32615125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic combinations of anticonvulsant agents: what is the evidence from animal experiments?
    Jonker DM; Voskuyl RA; Danhof M
    Epilepsia; 2007 Mar; 48(3):412-34. PubMed ID: 17346245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mind the Curve: Dose-Response Fitting Biases the Synergy Scores across Software Used for Chemotherapy Combination Studies.
    Fuentealba-Manosalva O; Mansilla M; Buelvas N; Martin-Martin A; Torres CG; López-Muñoz RA
    Int J Mol Sci; 2023 Jun; 24(11):. PubMed ID: 37298656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extracting falsifiable predictions from sloppy models.
    Gutenkunst RN; Casey FP; Waterfall JJ; Myers CR; Sethna JP
    Ann N Y Acad Sci; 2007 Dec; 1115():203-11. PubMed ID: 17925353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.